Endocrine Abstracts

Aim: To quantify the effect of pegvisomant on glucose homeostasis, lipid profile and disease activity in acromegaly.Methods: 5 Patients with active acromegaly after surgery, radiotherapy and somatostatin analogs were included. Somatostatin analogs were withdrawn 6 weeks before starting pegvisomant and it was initially administered subcutaneously at doses of 10 mg daily. Doses were progressively increased every 3 to 4 weeks until IGF1 normalization. Gluco...

Introduction: Hyponatremia is the most common electrolyte disorder in hospitalized patients. SIADH is characterized by euvolemic hyponatremia with sodium and urine osmolality inappropriately high. The selective antagonist of the vasopressin V2 receptor (tolvaptan) helps to eliminate water free of solute (aquaresis), being effective in treating this condition.Objetive: Evaluate the efficacy and safety of tolvaptan in the treatment of SIADH.<p class="a...

Obesity is emerging as a prevalent cause of chronic liver damage, which can lead to the development of metabolic-associated fatty liver disease (MAFLD), nonalcoholic steatohepatitis (NASH), or even hepatocellular carcinoma (HCC). Increasing evidence suggests a profound dysregulation of the splicing machinery (spliceosome and splicing factors) in these pathologies; however, the role of PRPF8, a pivotal spliceosome element, has not been described in chronic liver pathologies. Th...